-
Mashup Score: 1ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer field - 2 month(s) ago
More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag into registrational testing in one of the most important oncology disease | More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag into registrational testing in one of the most important disease areas—first-line non-small cell lung cancer.
Source: www.fiercepharma.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Patient Advocacy Honorees - 2 month(s) ago
The Patient Advocacy category of the Fierce 50 honors those who champion the rights and needs of patients, ensuring their voices aren’t just heard, but are driving real change. These honorees are the backbone of patient-centered care, working across healthcare and biopharma to amplify the concerns of those who too often go unnoticed. | These honorees are the backbone of patient-centered care, working across healthcare and biopharma to amplify the concerns of those who too often go unnoticed.
Source: www.fiercepharma.comCategories: General Medicine News, General NewsTweet-
The Patient Advocacy category of the Fierce 50 honors those who champion the rights and needs of patients, ensuring their voices aren’t just heard, but are driving real change. Read more about these honorees who are the backbone of patient-centered care: https://t.co/naY5zPh2ti
-
-
Mashup Score: 2Breakthroughs Honorees - 2 month(s) ago
The lives of countless people around the world are better today thanks to the drive of this year’s Breakthroughs honorees. These individuals and organizations are true architects of progress, fully aware that meaningful success doesn’t come quickly or easily. | The lives of countless people around the world are better today thanks to the drive of this year’s Breakthroughs honorees.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet-
The lives of countless people around the world are better today thanks to the drive of this year’s Fierce 50 Breakthroughs honorees. Read more about these 10 companies and individuals: https://t.co/KF3JPByhP4
-
-
Mashup Score: 16Health Equity Honorees - 2 month(s) ago
Disparities in healthcare access and outcomes continue to challenge communities and specific patient populations across the nation. The trailblazers we’re celebrating as Health Equity honorees are leading the charge toward meaningful change. | This diverse group of honorees is on a mission to push for systemic changes that underpin equitable healthcare.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet-
From tireless advocacy for equity in medical education to transformative investments in underserved populations, the Fierce 50 Health Equity honorees are reshaping the future of healthcare and dismantling barriers to care. https://t.co/0VOzsllwcL
-
-
Mashup Score: 2The Fierce 50 of 2024 - 2 month(s) ago
I’m honored to introduce the second edition of the Fierce 50, where we once again spotlight the innovators and leaders driving the future of healthcare, pharma and biotech. This year’s honorees are a testament to the unwavering dedication and creativity that push these industries forward. | In this year’s Fierce 50 special report, we are highlighting the innovators and leaders who are shaping the future of healthcare, pharma and biotechnology. This year’s honorees demonstrate unwavering dedication and creativity, propelling these industries forward.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet-
Today, we've unveiled the Fierce 50 of 2024, shining a spotlight on the people and companies who are driving meaningful change in healthcare, pharma and biotech https://t.co/1Yb3eLB3XX
-
-
Mashup Score: 0
After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy (semaglutide) are starting to get back on track. | Novo’s semaglutide cut the risk of combined cardiovascular death or worsening heart failure events by 31%, based on an incident rate of 5.4% in semaglutide patients versus 7.5% in those on placebo, the company said Friday. Semaglutide also led to a 41% lower risk of worsening HF, according to a pooled analysis of four Novo Nordisk trials.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet-
Novo rekindles #heartfailure hopes for semaglutide with new pooled analysis | #GLP1s https://t.co/xv3dl9Q32H
-
-
Mashup Score: 0
Late last year, Novo Nordisk responded to a growing shortage of popular Ozempic with a plan to cut down on production of its older diabetes med Victoza to make room for more Ozempic. | The company and the European Medicines Agency warned European healthcare providers to continue limiting new patient prescriptions until the shortages let up.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet-
In #Europe, shortages of Novo Nordisk's #Ozempic to persist into Q4: letter | #pharma #GLP1s #weightloss https://t.co/bHOE5ynWtn
-
-
Mashup Score: 3Biogen to seek approval for high-dose version of SMA stalwart Spinraza after trial win - 2 month(s) ago
Over the last decade, three blockbuster drugs—Biogen’s Spinraza, Roche’s Evrysdi and Novartis’ gene therapy Zolgensma—have transformed the treatment landscape for spinal muscular atrophy (SMA). | Biogen revealed that a portion of its phase 2/3 DEVOTE study met its primary endpoint, as a higher dose of Spinraza improved the motor function of treatment-naive infants with spinal muscular atrophy.
Source: www.fiercepharma.comCategories: General Medicine News, Rare DiseaseTweet-
RT @FiercePharma: Biogen to seek approval for high-dose version of SMA stalwart Spinraza after trial win https://t.co/6KuXXVAVRt
-
-
Mashup Score: 0Novartis taps Lindy to turn biologic drugs into at-home injectables, puts nearly $1B on the line - 2 month(s) ago
Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs. | Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet-
"Novartis taps Lindy to turn their biologic drugs into at-home injectables"... ... as disintermediation of "Big Healthcare" continues. https://t.co/KJsqQbNIQV
-
-
Mashup Score: 0Eli Lilly rolls out direct patient access to weight loss star Zepbound—at a deep discount - 2 month(s) ago
Eli Lilly has come up with a new way of supplying its popular weight-loss drug Zepbound that the company hopes could expand access while addressing other issues such as high prices and off-label co | Eli Lilly is offering its popular weight-loss drug Zepbound directly to consumers at a discount through its own online pharmacy. The company hopes the move could expand access while addressing other issues such as high prices and off-label cosmetic usage.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet-
.@EliLillyandCo rolls out direct patient access to #weightloss star Zepbound—at a deep discount | #DTC #D2C #pharma https://t.co/RPHwhlrw9Y
-
RT @dose_of_naz: #ESMO24: #BMS moves PD-1/LAG-3 combo #Opdualag (#Opdivo/#relatlimab) into #Phase3 in #1L #NSCLC https://t.co/M7LPt1nVQX